Covering CMC Dossier, Elinzanetant, Authorisation, Drug Approval, Therapeutic Product Registration. Explore pivotal regulatory updates in CMC dossier standards, Elinzanetant authorisation, drug approval pathways, and therapeutic product registration across ASEAN markets. Insights include digital dossier submissions and conditional vaccine authorisations.
Regulatory news, updates, and insights for countries in the ASEAN region presented by the Carver Agents team
Welcome to Carver's ASEAN Regulatory Updates for April 05, 2026.
The Monetary Authority of Singapore announced the introduction of revised Notice 133 on Valuation and Capital Framework, effective March 31, 2026. Key refinements include a new capital treatment for infrastructure investments, adjustments to the treatment of structured products, and equity counter-cyclical adjustments. The Monetary Authority of Singapore is also conducting ongoing consultations on third party risk and operational risk management guidelines. Emphasis has been placed on fair dealing and improving customer communication. Additionally, the authority is developing artificial intelligence risk management guidelines and support platforms.
Effective April 1, 2026, the Health Sciences Authority of Singapore has mandated the use of eCTD version 1.1 as the official standard for dossier submissions related to therapeutic product registration. From June 1, 2026, applicants must provide an official letter declaring no known quality defects in the Chemistry, Manufacturing, and Controls package. Applicants are required to submit dossiers via the official portal using the SG-HSA eCTD version 1.1 and refer to updated guidance documents for detailed submission requirements.
In Malaysia, the Governor delivered a keynote address at the Central Banking Meetings emphasizing that central banks must evolve from being solely stewards of stability to architects of resilience. The Governor called for the adoption of integrated policy frameworks that recognize structural economic forces, strengthening cyber resilience and governance around artificial intelligence and data risks, and enhancing coordination across monetary, fiscal, structural, and prudential policies.
Indonesia's National Agency of Drug and Food Control, known as BPOM, is promoting a conditional marketing authorization approach for vaccines following phase 1 and 2 clinical trials. The agency emphasizes balancing innovation, safety, and public trust in regulatory decisions and enhancing collaboration between academia, industry, and government.
The Philippines' Technical Working Group has launched a public consultation on the Initial Access List to ensure fair and non-discriminatory access to essential digital infrastructure and services. Stakeholders are invited to submit inputs as stipulated in Rule VI of the Implementing Rules and Regulations of Republic Act No. 12234.
That wraps up today's regulatory updates. Visit carveragents.ai for more information.